BPDCNinfo

Dedicated to raising awareness of blastic plasmacytoid dendritic cell neoplasm (BPDCN)—a hematologic cancer that can be dangerously unseen.

[BPDCNinfo @BPDCNInfo]

Dermatologists, pathologists, and hematologists all play a key role in identifying and diagnosing blastic plasmacytoid dendritic cell neoplasm (#BPDCN). In honor of #RareCancerDay, learn how different specialists can play a role in recognizing this often-misdiagnosed disease.

[BPDCNinfo @BPDCNInfo]

Blastic plasmacytoid dendritic cell neoplasm (#BPDCN) is a rare #bloodcancer that can present with leukemia-like symptoms. In recognition of #WorldLeukemiaDay, please review the key differences between BPDCN and leukemia by visiting our website.

[BPDCNinfo @BPDCNInfo]

Do you know that cell surface marker CD123 is a key indicator of blastic plasmacytoid dendritic cell neoplasm (#BPDCN)? As a result, we recognize today—1/23—as #BPDCNDay to raise awareness about this #raredisease. Learn more about BPDCN by visiting our website.

[BPDCNinfo @BPDCNInfo]

It’s #BPDCNday, a time to raise awareness of blastic plasmacytoid dendritic cell neoplasm. The #BPDCN community of hematologist-oncologists, pathologists, dermatologists, and dedicated researchers continue to extend our understanding of this rare #bloodcancer.

[BPDCNinfo @BPDCNInfo]

85% to 90% of patients with blastic plasmacytoid dendritic cell neoplasm (#BPDCN), a rare #bloodcancer, present with skin lesions. #Dermatologists: learn about the signs and symptoms of the disease so you are prepared to spot this uncommon hematologic malignancy.

[BPDCNinfo @BPDCNInfo]

When testing for suspected cases of #bloodcancer, #pathologists should consider adding marker CD123 to blood tests to help identify and diagnose blastic plasmacytoid dendritic cell neoplasm (#BPDCN). Learn more about important BPDCN indicators on our website.

[BPDCNinfo @BPDCNInfo]

A key component of confirming a blastic plasmacytoid dendritic cell neoplasm (#BPDCN) diagnosis is identifying a specific compatible immunophenotype—CD123—present in a patient by #hematologists. Learn more about hematology’s role in BPDCN diagnosis by visiting our website.

[BPDCNinfo @BPDCNInfo]

Dermatologists, pathologists, and hematologists all play a key role in identifying and diagnosing blastic plasmacytoid dendritic cell neoplasm (#BPDCN). In honor of #RareCancerDay, learn how different specialists can play a role in recognizing this often-misdiagnosed disease.

[BPDCNinfo @BPDCNInfo]

Blastic plasmacytoid dendritic cell neoplasm (#BPDCN) is a rare #bloodcancer that can present with leukemia-like symptoms. In recognition of #WorldLeukemiaDay, please review the key differences between BPDCN and leukemia by visiting our website.

[BPDCNinfo @BPDCNInfo]

Blastic plasmacytoid dendritic cell neoplasm (#BPDCN) is a rare and aggressive #bloodcancer. Head to our website to find out more about the signs and symptoms, the diagnostic process, and additional disease resources for BPDCN.

[BPDCNinfo @BPDCNInfo]

Diagnosing a #raredisease can require multiple health care professionals. For blastic plasmacytoid dendritic cell neoplasm (#BPDCN), it takes help from dermatologists, pathologists, and hematologists for a diagnosis. Learn more about your role in BPDCN diagnosis on our website.

[BPDCNinfo @BPDCNInfo]

It’s #BPDCNday, a time to raise awareness of blastic plasmacytoid dendritic cell neoplasm. The #BPDCN community of hematologist-oncologists, pathologists, dermatologists, and dedicated researchers continue to extend our understanding of this rare #bloodcancer.

[BPDCNinfo @BPDCNInfo]

On this #WorldLeukemiaDay, let's shed light on a rare and aggressive form of leukemia, blastic plasmacytoid dendritic cell neoplasm (#BPDCN). BPDCN is often misdiagnosed as more common hematologic cancers, including acute myeloid leukemia (AML) and leukemia cutis. #WLD23

[BPDCNinfo @BPDCNInfo]

A blood cancer with #dermatologic presentation? 85-90% of #BPDCN patients present with skin lesions. This #BloodCancerAwarenessMonth, let's shine a light on BPDCN and other blood cancers, because early and accurate diagnosis may take a multidisciplinary effort.

[BPDCNinfo @BPDCNInfo]

#Dermatologists may be the first clinicians to encounter signs of blastic plasmacytoid dendritic cell neoplasm (#BPDCN), #raredisease. Would you recognize BPDCN? Learn the signs and symptoms on our website.

[BPDCNinfo @BPDCNInfo]

Tuesday’s #BPDCN quiz covered the signature marker triad that distinguishes the #raredisease from others with similar symptoms. You’re right if you answered B! Research has shown the importance of including CD123 along with CD4 and CD56 in BPDCN diagnostic panels.* #hemonc

[BPDCNinfo @BPDCNInfo]

Since #BPDCN is a #raredisease, let’s test to see if you know its key distinguishing features from other #hematological cancers. (HINT: BPDCN can include other markers, such as TCL1, TCF4, and CD303 [BDCA2]).

Which one is NOT part of the signature BPDCN marker triad?

[BPDCNinfo @BPDCNInfo]

Our appreciation goes to the National Organization for Rare Diseases (@RareDiseases) for their support of #raredisease communities. The #BPDCN community is grateful for their commitment to improving the lives of all people affected by a rare disease!

[BPDCNinfo @BPDCNInfo]

#Pathologists play a key role in the diagnosis of blastic plasmacytoid dendritic cell neoplasm (#BPDCN), as it shares characteristics with other more common blood cancers, including AML, ALL, leukemia cutis, MDS, CMML, and NK/T-cell lymphoma.

[BPDCNinfo @BPDCNInfo]

As we move on from Rare Disease Awareness month, remember to keep the signs of a #raredisease such as blastic plasmacytoid dendritic cell neoplasm (#BPDCN) at the forefront all year long. With your support in raising awareness, the BPDCN community could have a brighter future.